<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236076</url>
  </required_header>
  <id_info>
    <org_study_id>PH-03</org_study_id>
    <nct_id>NCT04236076</nct_id>
  </id_info>
  <brief_title>Assessing Exercise Capacity After PulseHaler™ Treatment in GOLD II-IV COPD Patients</brief_title>
  <official_title>Assessing Exercise Capacity After PulseHaler™ Treatment in Chronic Obstructive Lung Disease (GOLD) II-IV of Chronic Obstructive Pulmonary Disease (COPD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respinova LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respinova LTD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, sham controlled, interventional study to evaluate the extent to which PulseHaler&#xD;
      improves the functional status of Chronic Obstructive Lung Disease (GOLD) II-IV Chronic&#xD;
      obstructive pulmonary disease (COPD) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of&#xD;
      COPD . PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies and for&#xD;
      pre-defined lengths of time.&#xD;
&#xD;
      The study is intended to evaluate the extent to which PulseHaler improves the functional&#xD;
      status of GOLD II-IV COPD patients after 4 weeks of treatment 3x / day.&#xD;
&#xD;
      And To evaluate the extent to which improvements are maintained over a subsequent 2 weeks&#xD;
      when treatments are tapered to 1x daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Constant Work Rate (CWR) Cardiopulmonary Exercise Test on cycle ergometer</measure>
    <time_frame>at day 29</time_frame>
    <description>Change from baseline in duration of constant work rate exercise testing (TLIM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary functions test- FEV1</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Change from baseline in Forced Expiratory Volume in 1 Second (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary functions test- FRC</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Change from baseline in Functional Residual Capacity (FRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary functions test - FEF25-75</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Change from baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary functions test- FVC</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Change from baseline in Forced Vital Capacity (FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test (CAT)</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Change from baseline in score on CAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients compliance rate to treatment</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Compliance rate and treatment timings self-reported through subject diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CWR Cardiopulmonary Exercise Test on cycle ergometer- TLIM</measure>
    <time_frame>at day 43</time_frame>
    <description>Change from baseline in duration of constant work rate exercise testing (TLIM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CWR Cardiopulmonary Exercise Test on cycle ergometer- VE</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Changes from baseline in Expired Ventilation (VE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CWR Cardiopulmonary Exercise Test on cycle ergometer- HR</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Changes from baseline in Hart Rate (HR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CWR Cardiopulmonary Exercise Test on cycle ergometer- SpO2</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Changes from baseline in Peripheral capillary oxygen saturation (SpO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CWR Cardiopulmonary Exercise Test on cycle ergometer- VT</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Changes from baseline in Tidal Volume (VT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CWR Cardiopulmonary Exercise Test on cycle ergometer- RR</measure>
    <time_frame>at day 29 and 43</time_frame>
    <description>Changes from baseline in Respiration Rate (RR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>PulseHaler™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive PulseHaler for home treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham PulseHaler - CONTROL group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive Sham device for home treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PulseHaler</intervention_name>
    <description>PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.</description>
    <arm_group_label>PulseHaler™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham - control</intervention_name>
    <description>Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.</description>
    <arm_group_label>Sham PulseHaler - CONTROL group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Investigator confirmation of GOLD II-IV COPD&#xD;
&#xD;
          -  Successful completion of Incremental Exercise Test (IET)&#xD;
&#xD;
          -  FEV1 &lt; 60% predicted&#xD;
&#xD;
          -  Post-bronchodilator FEV1/FVC ≤ 0.7&#xD;
&#xD;
          -  55-75 years old&#xD;
&#xD;
          -  Signed informed consent by subject (required cognitive capacity)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  SpO2&lt;80% at IET&#xD;
&#xD;
          -  Unable to achieve a CWR test duration at visit 2 between 3 and 8 minutes&#xD;
&#xD;
          -  Exercise limitation unrelated to diagnosis of COPD&#xD;
&#xD;
          -  Systemic (oral, IV, IM) steroid use for acute exacerbation in the 30 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Baseline CAT Score &lt;10&#xD;
&#xD;
          -  Women at the age of fertility, who are pregnant, or plan pregnancy, or do not use&#xD;
             contraceptives&#xD;
&#xD;
          -  Severe cardiac disease, e.g., Congestive Heart Failure grade , hemodynamic&#xD;
             instability,&#xD;
&#xD;
          -  Acute myocardial infarction within last 3 months&#xD;
&#xD;
          -  Coronary artery bypass graft within last 3 months&#xD;
&#xD;
          -  Epilepsy, raised intracranial pressure, acute sinusitis or nosebleed&#xD;
&#xD;
          -  Pulmonary embolism, untreated air leaks, tension pneumothorax, bronchopleural fistula,&#xD;
             active hemoptysis, pulmonary haemorrhage, Large pulmonary bullae, intrathoracic&#xD;
             obstruction from tumor or foreign body&#xD;
&#xD;
          -  Unhealed dental, head, neck, ear, nose &amp; throat, thoracic or upper gastro-intestinal&#xD;
             tract surgery or trauma&#xD;
&#xD;
          -  Unhealed broken ribs&#xD;
&#xD;
          -  Esophageal varices&#xD;
&#xD;
          -  Anxiety, Depression, history of Mental illness&#xD;
&#xD;
          -  Dependence on positive pressure ventilation (i.e. 24/7 non-invasive ventilation).&#xD;
&#xD;
          -  Cannot perform spirometry&#xD;
&#xD;
          -  Enrollment in another interventional study&#xD;
&#xD;
          -  Any medical condition for which the investigator deems the subject unable to&#xD;
             participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Yarmolovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaplan Medical Center, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dalia Givony, MSC</last_name>
    <phone>+972-54-5449235</phone>
    <email>dalia@respinova.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cliff Annsel</last_name>
    <email>Cliff@respinova.com</email>
  </overall_contact_backup>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

